TRPC1 is upregulated in several cancer types, including breast cancer. Since it contributes to Ca²⁺ influx, its overexpression can enhance signaling pathways that drive: -Proliferation -Migration & invasion -Epithelial–mesenchymal transition (EMT) -Chemoresistance Breast cancer cell lines MCF-7 (ER⁺, luminal type) -TRPC1 is expressed and contributes to store-operated calcium entry (SOCE). -Silencing or inhibiting TRPC1 tends to reduce proliferation and increase sensitivity to apoptosis. MDA-MB-231 (triple-negative, invasive type) -TRPC1 is generally upregulated compared to non-tumorigenic breast epithelial cells (like MCF10A or HBL-100). -Promotes migration and invasion through calcium-dependent activation of signaling pathways (e.g., NFAT, ERK, AKT). -Knockdown reduces motility and metastatic potential in vitro. HBL-100 (SV40-transformed, non-malignant reference) -TRPC1 expression is lower than in true malignant lines like MDA-MB-231. -Often used as a “control” to highlight that TRPC1 is upregulated during malignant transformation.